Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (14717)	9/18/2000 1:07:51 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Yes, I imagine xoma missing many million$ and the company stock at $0.5 instead of $12. Face it Gw, it is not lack of understanding, it was a clear BUSINESS decision, no knowledge of trial failure provided xoma with time to survive and get strong. I have no problem with it. The company decision in HIDING the data but to the few, and probably ilegal too under the SEC laws, and definitely unfair to shareholders, and profiting for many of the lucky ones like Sutro, Pj, the "privates", analysts, etc, to the expense of many shareholders THAT is the result. Clearly, You have a problem accepting the above as a pure BUSINESS decision, nothing to do with the science of it, neither regulatory approval that xoma most probably KNEW well it was going to be of NEGATIVE consecuences. Baxter is not idiot, they pay for the future of bpi, not for the meningopIII trial. Clearly, a second rate pharmaceutical was willing to do it, baxter did. And the * in the baxoma deal for sure has the fda rejection accounted for, besides the know milestones baxter will not pay cause bpi for meningo development is for long and maybe forever stall.